Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mechanisms and Interventions Addressing Accelerated Cardiovascular Disease Risk in Endometriosis
NCT05069740Phase 1Recruiting
- Sponsor
- The Pennsylvania State University
- Start
- Jan 2022
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of Amigesic in endometriosis (2 arms), sponsored by The Pennsylvania State University. Primary endpoints: Cutaneous vascular conductance at 5 days, Brachial artery diameter and blood flow velocity at 5 days and 2 more. Started Jan 2022; status: recruiting.
02
Drugs
Amigesic
03
Conditions
endometriosis
Beyond the preview
Go deeper on NCT05069740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05069740.